XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Net income $ 78,644 $ 57,167
Adjustment to reconcile net income to net cash provided by operating activities:    
Depreciation 17,137 15,818
Amortization of intangible assets 21,554 25,525
Amortization of original issue discount and deferred financing costs 2,400 3,229
Loss on change in contractual interest rate [1] 2,957
Deferred income taxes 28,703 22,909
Share-based compensation expense [2] 8,402 7,805
Other 361 (45)
Net changes in operating assets and liabilities, net of acquisitions:    
Accounts receivable (70,108) (11,642)
Inventories 16,738 6,177
Other assets (3,852) 2,663
Accounts payable (206) (2,618)
Accrued wages and employee benefits 6,288 4,981
Other accrued liabilities 17,319 1,341
Excess tax benefits from equity awards (661) (6,754)
Net cash provided by operating activities 122,719 129,513
Investing activities    
Proceeds from sale of property and equipment 77 1,349
Expenditures for property and equipment (16,658) (20,847)
Acquisitions of businesses, net of cash acquired 1,257 (61,386)
Net cash used in investing activities (15,324) (80,884)
Financing activities    
Proceeds from short-term borrowings 74,443 14,117
Proceeds from long-term borrowings 3,069
Repayments of short-term borrowings (80,952) (8,244)
Repayments of long-term borrowings and capital lease obligations (13,051) (10,976)
Stock repurchases (30,012) (99,934)
Payment of debt issuance costs (1,517)
Cash dividends paid (76)
Taxes paid related to the net share settlement of equity awards (2,479) (12,308)
Proceeds from exercise of stock options 1,717
Excess tax benefits from equity awards 6,754
Net cash used in financing activities (48,782) (110,667)
Effect of exchange rate changes on cash and cash equivalents 2,895 344
Net increase (decrease) in cash and cash equivalents 61,508 (61,694)
Cash and cash equivalents at beginning of period 67,272 115,857
Cash and cash equivalents at end of period $ 128,780 $ 54,163
[1] For the three and nine month periods ended September 30, 2016, represents a non-cash loss relating to the continued 25 basis point increase in borrowing costs as a result of the credit agreement leverage ratio remaining above 3.0 times based on projections at that time.
[2] Represents share-based compensation expense to account for stock options, restricted stock and other stock awards over their respective vesting periods.